Secondary Prevention of Coronary Heart Disease in the Elderly

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1867-1876

  Dornbrook Lavender, Kimberly A ^a,b   Roth, Mary T ^a   Pieper, John A ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b PPD Medical Communications   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Coronary heart disease, secondary prevention; Elderly

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GEMFIBROZIL; LISINOPRIL; METOPROLOL; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PRAVASTATIN; PROPRANOLOL DERIVATIVE; RAMIPRIL; SIMVASTATIN; STATIN; SULFINPYRAZONE; SULOCTIDIL; TICLOPIDINE; TIMOLOL; WARFARIN; ZOFENOPRIL;

ACUTE KIDNEY FAILURE; AGED; AGING; ASSOCIATION; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL INTOLERANCE; GERIATRIC PATIENT; HEART EJECTION FRACTION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MEDLINE; MORBIDITY; MORTALITY; MYOSITIS; PATIENT COMPLIANCE; PATIENT MONITORING; POPULATION; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED STATES; VASCULAR DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS;

EID: 0345275900     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D026     Document Type: Review

References (48)

1. American Heart Association. 2002 heart and stroke statistical update. www.americanheart.org/statistics (accessed 2002 Jan 23).
2. Dalal D, Robbins JA. Management of hyperlipidemia in the elderly population: an evidence-based approach. South Med J 2002;95:1255-61.
3. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092-7.
4. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Unstable Angina). 2002. www.acc.org/clinical/guidelines/unstable/angina.pdf (accessed 2002 May 15).
5. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
6. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age). An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735-43.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
8. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
9. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Diverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:84-9.
10. Moore JG, Bjorkman DJ, Mitchell MD, Avots-Avontins A. Age does not influence acute aspirin-induced gastric mucosal damage. Gastroenterology 1991;100:1626-9.
11. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik T, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot from the Cooperative Cardiovascular Project. JAMA 1996;273:1509-14.
12. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcome. Ann Intern Med 1996;124:292-8.
13. Aronow WS. Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1998;46:615-6.
14. Ghosh S, Ziesmer V, Aronow WS. Underutilization of aspirin, betablockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. J Gerontol 2002;57:M398-M400.
15. Rich MW. Therapy for acute myocardial infarction. Clin Geriatr Med 1996;12:141-68.
16. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981;2:823-7.
17. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 1982;247:1707-14.
18. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
19. Gundersen T, Abrahamsen AM, Kjekshus J, Ronnevik PK for the Norwegian Multicentre Study Group. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-84.
20. Pederson TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-8.
21. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. β-Blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med 1992;93:605-10.
22. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
23. Krumholz HM, Radford MJ, Wang Y, Chen B, Heiat A, Marciniak TA. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9.
24. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
25. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study. Circulation 1997;96:4211-8.
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
27. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin in cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events Trial. Ann Intern Med 1998;129:681-9.
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
29. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-40.
30. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
31. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with sinivastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial. Lancet 2002;360:7-22.
32. Shepard J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
33. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly. J Am Coll Cardiol 2002;40:1777-85.
34. Mendelson G, Aronow WS. Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. J Am Geriatr Soc 1998;46:1128-31.
35. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dl. Am J Cardiol 1998;82:668-9,A6,A8.
36. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
38. Chong PJ, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001;111:390-400.
39. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscleros Suppl 2002;3:35-40.
40. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results from the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
41. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
42. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
43. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
45. Krumholz HM, Vaccarino V, Ellerbeck EF, Kiefe C, Hennen J, Kresowik TF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol 1997;79:581-6.
46. Mendelson G, Aronow WS. Underutilization of angiotensin-converting enzyme inhibitors in older patients with Q-wave anterior myocardial in farction in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1998;46:751-2.
47. The American Heart Association's Get with the Guidelines. www. americanheart.org/presenter.jhtml?identifier= 1165 (accessed 2003 May 4).
48. Strandberg TE, Pitkala K, Berglind S, Nieminen MS, Tilvis RS. Multifactorial cardiovascular disease prevention in patients aged 75 years and older: a randomised controlled trial. Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Am Heart J 2001;142:945-51.